Search Results - "Wasfi, Yasmine"

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis by Gordon, Kenneth B, Duffin, Kristina Callis, Bissonnette, Robert, Prinz, Jörg C, Wasfi, Yasmine, Li, Shu, Shen, Yaung-Kaung, Szapary, Philippe, Randazzo, Bruce, Reich, Kristian

“…The results of this phase 2 randomized trial suggest that guselkumab, an anti–interleukin-23 monoclonal antibody, may be an effective therapy for psoriasis and…”
Get full text

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial by Blauvelt, Andrew, MD, MBA, Papp, Kim A., MD, PhD, Griffiths, Christopher E.M., MD, Randazzo, Bruce, MD, PhD, Wasfi, Yasmine, MD, PhD, Shen, Yaung-Kaung, PhD, Li, Shu, PhD, Kimball, Alexa B., MPH, MD

“…Background Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives We sought…”
Get full text

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial by Reich, Kristian, MD, Armstrong, April W., MD, MPH, Foley, Peter, MD, Song, Michael, MD, Wasfi, Yasmine, MD, PhD, Randazzo, Bruce, MD, PhD, Li, Shu, PhD, Shen, Y.-K., PhD, Gordon, Kenneth B., MD

“…Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis. Objective We sought to assess…”
Get full text

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis by Sofen, Howard, MD, Smith, Stacy, MD, Matheson, Robert T., MD, Leonardi, Craig L., MD, Calderon, Cesar, PhD, Brodmerkel, Carrie, PhD, Li, Katherine, MS, Campbell, Kim, PhD, Marciniak, Stanley J., MBA, Wasfi, Yasmine, MD, PhD, Wang, Yuhua, PhD, Szapary, Philippe, MD, Krueger, James G., MD, PhD

“…Background IL-23 expression is increased in psoriatic lesions and might regulate TH 17 T-cell counts in patients with psoriasis. Objectives We sought to test a…”
Get full text

Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility by Liao, Shu-Yi, Jacobson, Sean, Hamzeh, Nabeel Y, Culver, Daniel A, Barkes, Briana Q, Mroz, Margarita, Macphail, Kristyn, Pacheco, Karin, Patel, Divya C, Wasfi, Yasmine S, Koth, Laura L, Langefeld, Carl D, Leach, Sonia M, White, Elizabeth, Montgomery, Courtney, Maier, Lisa A, Fingerlin, Tasha E

“…Abstract Sarcoidosis is a complex systemic disease. Our study aimed to (1) identify novel alleles associated with sarcoidosis susceptibility; (2) provide an…”
Get full text

P021: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory and non-ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02) by Kishnani, Priya, Schoser, Benedikt, Bratkovic, Drago, Clemens, Paula, Goker-Alpan, Ozlem, Ming, Xue, Roberts, Mark, Vorgerd, Matthias, Sivakumar, Kumaraswamy, van der Ploeg, Ans, Goldman, Mitchell, Wright, Jacquelyn, Holdbrook, Fred, Jain, Vipul, Das, Sheela Sitaraman, Wasfi, Yasmine, Mozaffar, Tahseen, Byrne, Barry

Get full text

A new tool to assess sarcoidosis severity by Wasfi, Yasmine S, Rose, Cecile S, Murphy, James R, Silveira, Lori J, Grutters, Jan C, Inoue, Yoshikazu, Judson, Marc A, Maier, Lisa A

“…Sarcoidosis is a granulomatous disorder primarily affecting the lung, but with frequent extrapulmonary organ involvement. There are no comprehensive scoring…”
Get more information

The efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma by Wasfi, Yasmine S, Villarán, César, de Tilleghem, Celine Le Bailly, Smugar, Steven S, Hanley, William D, Reiss, Theodore F, Knorr, Barbara A

“…Summary Leukotriene B4 (LTB4 ) is a potent inflammatory mediator in asthma, and is increased in more severe asthma. Targeting LTB4 , in addition to cysteinyl…”
Get full text

A 45-year-old man with severe dysphagia and pulmonary infiltrates by Wasfi, Yasmine S, Margolis, Mitchell L

Get more information

Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast by Wasfi, Yasmine S, Kemp, James P, Villarán, César, Massaad, Rachid, Xin, Wenjing, Smugar, Steven S, Knorr, Barbara A, Philip, George

“…Single-dose montelukast attenuates exercise-induced bronchoconstriction (EIB) in adults within 2 hours postdose and lasting through 24 hours. This study…”
Get more information

Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003) by Kushlaf, Hani, Bratkovic, Drago, Byrne, Barry, Claeys, Kristl, Diaz-Manera, Jordi, Dimachkie, Mazen, Kishnani, Priya, Roberts, Mark, Toscano, Antonio, Castelli, Jeff, Holdbrook, Frederick, Das, Sheela, Wasfi, Yasmine, Schoser, Benedikt, Mozaffar, Tahseen

“…Abstract only…”
Get full text

Plasma total GAA protein PK profiles differ between cipaglucosidase alfa/miglustat and alglucosidase alfa by Johnson, Franklin K., Kang, Jia, Mondick, John, Sitaraman, Sheela, Wasfi, Yasmine, Goldman, Mitchell, Castelli, Jeff, Do, Hung

Get full text

Long-term Follow-up of Cipaglucosidase Alfa/Miglustat in Ambulatory Patients with Pompe Disease: An Open-label Phase I/II Study (ATB200-02) (S48.007) by Mozaffar, Tahseen, Schoser, Benedikt, Kishnani, Priya, Bratkovic, Drago, Clemens, Paula R., Goker-Alpan, Ozlem, Ming, Xue, Roberts, Mark, Sivakumar, Kumaraswamy, Van Der Ploeg, Ans, Goldman, Mitchell, Wright, Jacquelyn, Holdbrook, Fred, Jain, Vipul, Sitaraman, Sheela, Wasfi, Yasmine, Byrne, Barry

“…Abstract only…”
Get full text

Population Pharmacokinetic Modeling of Guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL‐23, in Patients with Moderate to Severe Plaque Psoriasis by Yao, Zhenling, Hu, Chuanpu, Zhu, Yaowei, Xu, Zhenhua, Randazzo, Bruce, Wasfi, Yasmine, Chen, Yang, Sharma, Amarnath, Zhou, Honghui

“…Psoriasis is a common inflammatory skin disorder that requires chronic treatment and is associated with multiple comorbidities. Guselkumab, a human…”
Get full text

Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease by Toscano, Antonio, Byrne, Barry J., Claeys, Kristl G., Diaz-Manera, Jordi, Dimachkie, Mazen M., Kishnani, Priya S., Kushlaf, Hani, Mozaffar, Tahseen, Roberts, Mark E., Hummel, Noemi, Holdbrook, Fred K., Shohet, Simon, Wasfi, Yasmine, Schoser, Benedikt

Get full text

Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL by Mozaffar, Tahseen, Bratkovic, Drago, Byrne, Barry J., Claeys, Kristl G., Diaz-Manera, Jordi, Dimachkie, Mazen M., Kishnani, Priya S., Kushlaf, Hani, Roberts, Mark E., Toscano, Antonio, Castelli, Jeffrey, Holdbrook, Fred K., Das, Sheela Sitaraman, Wasfi, Yasmine, Schoser, Benedikt

Get full text

Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02) by Byrne, Barry J., Schoser, Benedikt, Kishnani, Priya S., Bratkovic, Drago, Clemens, Paula R., Goker-Alpan, Ozlem, Ming, Xue, Roberts, Mark, Vorgerd, Matthias, Sivakumar, Kumaraswamy, van der Ploeg, Ans T., Goldman, Mitchell, Wright, Jacquelyn, Holdbrook, Fred, Jain, Vipul, Benjamin, Elfrida R., Johnson, Franklin, Das, Sheela Sitaraman, Wasfi, Yasmine, Mozaffar, Tahseen

“…Cipaglucosidase alfa plus miglustat (cipa + mig) is a novel, two-component therapy for Pompe disease. We report data from the Phase I/II ATB200-02 study for up…”
Get full text

Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02) by Byrne, Barry J., Schoser, Benedikt, Kishnani, Priya, Bratkovic, Drago, Clemens, Paula R., Goker-Alpan, Ozlem, Ming, Xue, Roberts, Mark, van der Ploeg, Ans T., Goldman, Mitchell, Wright, Jacquelyn, Holdbrook, Fred, Jain, Vipul, Sitaraman, Sheela, Wasfi, Yasmine, Mozaffar, Tahseen

Get full text

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial by Armstrong, April, Puig, Luis, Langley, Richard, Tsai, Tsen Fang, Song, Michael, Wasfi, Yasmine, Jiang, Jingzhi, Li, Shu, Han, Chenglong

“…Purpose: The Psoriasis Symptoms and Signs Diary (PSSD) is a patient-reported instrument that assesses severity of six symptoms (itch, skin tightness, burning,…”
Get full text

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07) by Schoser, Benedikt, Kishnani, Priya S., Bratkovic, Drago, Byrne, Barry J., Claeys, Kristl G., Díaz-Manera, Jordi, Laforêt, Pascal, Roberts, Mark, Toscano, Antonio, van der Ploeg, Ans T., Castelli, Jeff, Goldman, Mitchell, Holdbrook, Fred, Sitaraman Das, Sheela, Wasfi, Yasmine, Mozaffar, Tahseen

“…The phase III double-blind PROPEL study compared the novel two-component therapy cipaglucosidase alfa + miglustat (cipa + mig) with alglucosidase alfa +…”
Get full text